Actinium Pharmaceuticals, Inc.(ATNM)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Actinium Pharmaceuticals, Inc. (ATNM) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ATNM at 36.5/100 on a 32-signal composite quality model, placing it at rank #2,266 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Actinium Pharmaceuticals, Inc. reports quarterly revenue of $35.0M, net income of $27.9M, an operating margin of 78.8%. Top institutional holders of ATNM by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, COMPASS FINANCIAL MANAGEMENT, MILLENNIUM MANAGEMENT, based on the most recent SEC filings. ATNM trades on the NYSE exchange and files with the SEC under CIK 1388320. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ATNM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Actinium Pharmaceuticals, Inc. directly from SEC EDGAR.